Evidence map›Paper›PMID 41032078›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Quantitative analysis of [

Huiyi Wei, Junqi Hu, Achi Haider, Junjie Wei, Jie Ma, Hao Lu, Yuefeng Li, Yuanfang Jiang, Haige Yi, Huanyu Gong and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Head-to-head comparison of [European journal of nuclear medicine and molecular imaging · 2026
    Article
  2. The predictive value ofEuropean journal of nuclear medicine and molecular imaging · 2026
    Article
  3. Article
  4. Radiosynthesis and Evaluation ofACS medicinal chemistry letters · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Huiyi Wei *Center of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine & Key laboratory of Basic and Translational Research on Radiopharmaceuticals, The First Affiliated Hospital of Jinan University, 510630, Guangzhou, China.
Junqi Hu *Center of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine & Key laboratory of Basic and Translational Research on Radiopharmaceuticals, The First Affiliated Hospital of Jinan University, 510630, Guangzhou, China.
Achi Haider *Department of Radiology and Imaging Sciences, Emory University, 1364 Clifton Rd, Atlanta, GA, 30322, USA.
Junjie WeiCenter of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine & Key laboratory of Basic and Translational Research on Radiopharmaceuticals, The First Affiliated Hospital of Jinan University, 510630, Guangzhou, China.
Jie MaCenter of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine & Key laboratory of Basic and Translational Research on Radiopharmaceuticals, The First Affiliated Hospital of Jinan University, 510630, Guangzhou, China.
Hao LuDepartment of Anesthesiology, The First Affiliated Hospital of Jinan University, 510630, Guangzhou, China.
Yuefeng LiGuangdong Landau Biotechnology Co. Ltd., Guangzhou Fenghuang Laboratory, 9th Floor, No. 78, Fenghuang Yihang Road, Huangpu District, 510700, Guangzhou, China.
Yuanfang JiangCenter of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine & Key laboratory of Basic and Translational Research on Radiopharmaceuticals, The First Affiliated Hospital of Jinan University, 510630, Guangzhou, China.
Haige YiCenter of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine & Key laboratory of Basic and Translational Research on Radiopharmaceuticals, The First Affiliated Hospital of Jinan University, 510630, Guangzhou, China.
Huanyu GongCenter of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine & Key laboratory of Basic and Translational Research on Radiopharmaceuticals, The First Affiliated Hospital of Jinan University, 510630, Guangzhou, China.
Zhiqiang TanCenter of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine & Key laboratory of Basic and Translational Research on Radiopharmaceuticals, The First Affiliated Hospital of Jinan University, 510630, Guangzhou, China.
Jian GongCenter of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine & Key laboratory of Basic and Translational Research on Radiopharmaceuticals, The First Affiliated Hospital of Jinan University, 510630, Guangzhou, China.
Bin GuoCenter of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine & Key laboratory of Basic and Translational Research on Radiopharmaceuticals, The First Affiliated Hospital of Jinan University, 510630, Guangzhou, China.
Xiaofei ZhengDepartment of Sports Medicine, The First Affiliated Hospital, Guangdong Provincial Key Laboratory of Speed Capability, The Guangzhou Key Laboratory of Precision Orthopedics and Regenerative Medicine, Jinan University, Guangzhou, China.
Hao XuCenter of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine & Key laboratory of Basic and Translational Research on Radiopharmaceuticals, The First Affiliated Hospital of Jinan University, 510630, Guangzhou, China. txh@jnu.edu.cn.
Hao WangDepartment of Anesthesiology, The First Affiliated Hospital of Jinan University, 510630, Guangzhou, China. drwanghao@yeah.net.
Lu WangCenter of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine & Key laboratory of Basic and Translational Research on Radiopharmaceuticals, The First Affiliated Hospital of Jinan University, 510630, Guangzhou, China. l_wang1009@foxmail.com.ORCID 0000-0002-8049-1991

Funding

Guangzhou Science and Technology Program of China 202206010106Guangzhou Science and Technology Program of China 2024A03J0828Guangzhou Science and Technology Program of China 2024A03J1042National Natural Science Foundation of China 82371998National Natural Science Foundation of China 82402345Open Program at Guangdong Provincial Key Laboratory of Research on Emergency in TCM 2023B1212060062Shanghai Key Laboratory of Molecular Imaging 18DZ2260400
6 · The paper itself

Abstract

purposeCholesterol 24-hydroxylase (CYP46A1) is a brain-specific enzyme catalyzes the conversion of cholesterol into 24S-hydroxycholesterol, thereby playing a pivotal role in maintaining cerebral cholesterol homeostasis. Dysregulation of this pathway has been implicated in various neurological disorders, including Alzheimer's disease, Huntington's disease, epilepsy, and depression. To enable quantitative assessment of CYP46A1 activity in vivo, a CYP46A1-targeted PET radiotracer with high specificity and favorable pharmacokinetics is envisioned. This study aimed to evaluate the metabolic stability, target specificity, and pharmacokinetic properties of [

methods[

results[

conclusion[

Indexed as

BrainCholesterol 24-HydroxylaseFluorine RadioisotopesPositron-Emission TomographyRadiopharmaceuticalsAnimalsFemaleLigandsMaleTissue DistributionCholesterol 24-HydroxylaseFluorine RadioisotopesLigandsRadiopharmaceuticalsCYP46A1Kinetic analysisNonhuman primatesPETReceptor occupancy

Identifiers

PMID41032078

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.